WIA
CRL icon

Wetzel Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Wetzel Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11
Closed -$2.98K – 273
2024
Q2 		$2.98K Hold
11
– – ﹤0.01% 679
2024
Q1 		$2.5K Hold
11
– – ﹤0.01% 808
2023
Q4 		$3K Buy
+11
New +$2.16K ﹤0.01% 770

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Wetzel Investment Advisors's CRL Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 11 shares — an estimated $2.98K sold.

Wetzel Investment Advisors first reported a position in CRL in Q4 2023 and held it in 3 quarters. The position peaked at $3K in Q4 2023. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 11 Charles River Laboratories shares in Q3 2024, an estimated $2.98K.
  • Wetzel Investment Advisors first reported a position in Charles River Laboratories in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's Charles River Laboratories position peaked at $3K in Q4 2023.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.